No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy.

Dominic PicettiJihoon KimWenhong ZhuWilliam J SandbornVipul JairathSiddharth Singh

Published in: Digestive diseases and sciences (2021)

5-ASAs are frequently continued long-term even after escalation to anti-metabolite therapy in patients with CD but offer no clinical benefit over stopping 5-ASA.

Keyphrases

stem cells
randomized controlled trial
mesenchymal stem cells
cell therapy
double blind